Released today, The Aging Myth is an explosive new book by noted scientist and anti-aging researcher Joseph Chang, Ph.D., that reveals how new genetic discoveries are challenging traditional anti-aging philosophies and helping people live younger longer. In The Aging Myth, Dr. Chang uses a conversational and accessible style to dispel common myths about aging and explains some of the latest groundbreaking research in the field.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nuskin/50881/
Marooned in a parallel universe in war-torn Lebanon, James Pollack finds a mysterious time-travelling medallion. Meanwhile, some fifty years in the future, his companions and former lover fight to stay alive. Earth has changed. The landscape is dangerous and genetic mutations have wiped out the male species. Will James be able to get his female companions safely home? Learn more about this book and the author: http://www.independentauthornetwork.com/andrew-man.html Thriller
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
In his new book, award-winning author Donovan Webster embarks on an epic journey to meet his ancestral human family, following the path set by his DNA some 60,000 years ago. Meeting the Family is part genetic science, part travelogue, and totally fascinating. Learn more about this book here: http://tinyurl.com/35rfr3x Non-fiction
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Amway North America today launched BODYKEY by NUTRILITE™, a weight management program rooted in genetics that reveals exactly how a person should eat to most effectively manage their weight.
BODYKEY by NUTRILITE weight loss plans are based on an individual’s unique genetic makeup. The new program combines eating well, fitness, nutrition and a take-at-home genetic test to determine if a person’s body responds better to cutting carbs, reducing fat or a balanced diet.
To view Multimedia News Release, go to http://www.multivu.com/players/English/60257-amway-bodykey/
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
The workbook addresses several concepts and starts with the prevention of relapse. The major part of the workbook is how to develop support systems for maintaining recovery that contribute to successful recovery. The text shows many elements that contribute to addiction. It goes into detail about the genetic aspects of addiction. There is also a segment of how executive functioning of the brain can get impaired with addiction that compromises judgment, impulse control, and the ability to organize. But these impairments can be temporary with practicing having good judgment and impulse control, since new neuropathways can develop with exercising these functions. The stages of recovery and change are reviewed as well as the twelve steps of Alcoholics Anonymous and Narcotics Anonymous. One chapter is dedicated to powerlessness and unmanageability. At the end of each chapter, there are references for the reader to consult that have been used for the content of the workbook chapters. Find out more at https://www.amazon.com/Successful-Recovery-Relapse-Prevention-McCausland-ebook/dp/B079648R6X Non-fiction, self-help
